DXA remains essential as the clinical standard for measuring bone mineral density and diagnosing osteoporosis. In the United States, the USPSTF recommends osteoporosis screening for women aged 65 years and older, as well as for postmenopausal women younger than 65 who are at increased fracture risk. DXA is central to this process because it helps clinicians identify normal bone density, osteopenia, and osteoporosis.
The Monitoring Gap
But DXA has one important limitation: it is a snapshot. It shows bone structure at one point in time. It does not directly show whether bone is actively being broken down or rebuilt today.This matters because bone is living tissue. A patient may be losing bone rapidly, responding well to treatment, or not responding at all, but those biological changes may not be visible on a DXA scan for months or even years. This delay creates a significant monitoring gap.
Beyond the Skeleton of Today
Even though DXA is powerful enough to serve as a key endpoint in osteoporosis drug development , it is not designed to be a frequent biological monitoring tool. It tells us where the skeleton is today, not always where bone metabolism is heading.For patients and families, this distinction is critical. The goal of osteoporosis care is not simply to receive a scan result. The goal is to prevent fractures before they happen, especially in older women whose mobility and independence can be permanently changed after a fall.
At MARA Nanotech, this is the scientific question that motivates our work: how can we complement structural bone information with more dynamic biological data?
In my next article, I will explain how bone turnover markers such as P1NP and β-CTX may help fill this monitoring gap between DXA scans.
References
1. U.S. Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures. 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening2. U.S. Food and Drug Administration. FDA Qualifies Total Hip Bone Mineral Density as Surrogate Endpoint for Osteoporosis Drug Development. 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-total-hip-bone-mineral-density-bmd-surrogate-endpoint-osteoporosis-drug-development
[MARA Global Insight]
"MARA Nanotech’s Global Health Reports are being updated sequentially on our official English blog (health.maranano.com). Be the first to explore the integration of global medical trends and cutting-edge nanotechnology."
[Visit MARA Official Site: https://www.maranano.com/]
About the Author: Dr. HeaYeon Lee is a nanobiosensor scientist and CEO of MARA Nanotech, dedicated to digitizing biological signals for precision health monitoring.
Medical Disclaimer: This article is for educational purposes only and is not intended as medical advice. Patients should consult a qualified healthcare professional before making decisions about osteoporosis screening, diagnosis, or treatment.
Note: Some conceptual images in this article were generated using AI to represent family narratives.
